Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avanir Pharmaceuticals (AVN) -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (148)	1/5/2006 4:07:39 PM
From: caly	Read Replies (1) \| Respond to of 166

AVANIR Pharmaceuticals Invites Investors to the 24th Annual JPMorgan Healthcare Conference Webcast Wednesday January 4, 4:00 pm ET SAN DIEGO--(BUSINESS WIRE)--Jan. 4, 2006--AVANIR Pharmaceuticals (AMEX:AVN - News) will be presenting at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2005, at 4:00 p.m. PT in San Francisco. AVANIR's President and Chief Executive Officer, Eric Brandt, will be presenting at the investor conference. The presentation will be available via a live webcast accessible through AVANIR's corporate website at www.avanir.com. To access the webcasts, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software. Archived versions of the presentations will be available until February 12, 2006. AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases. AVANIR previously announced positive results in the second of two required Phase III clinical trials of Neurodex(TM), an investigational new drug for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a Phase III clinical trial for Neurodex as a potential treatment for diabetic neuropathic pain, a second indication for Neurodex. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.